News >

Infigratinib Findings in IHC Highlight Importance of Molecular Testing

Angelica Welch
Published: Thursday, Nov 01, 2018

Milind Javle, MD

Milind Javle, MD
In updated results of a phase II study of infigratinib, the selective pan-FGFR kinase inhibitor showed a manageable toxicity profile and clinically meaningful activity following chemotherapy in patients with intrahepatic cholangiocarcinoma (IHC).

Javle, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discussed the findings from this phase II study and emphasized the importance of molecular testing in cholangiocarcinoma.

OncLive: Could you begin with some background on this drug and the phase II trial?

Javle: The molecular profiling of cholangiocarcinoma is transforming this disease, as it has more actionable mutations than most other gastrointestinal cancers. We began this FGFR-directed trial close to 5 years ago, we really thought that this would be a difficult trial to implement because there has never been a targeted therapy trial in cholangiocarcinoma against a specific genetic mutation. FGFR fusions occur in about 15% of IHC. It is a rare subset in a rare disease. We thought this would be hard to do, but we finished the enrollment in less than 2 years.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication